Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas
Background: We have previously shown that 3-Deazaneplanocin A (DZNep) induces apoptosis in chondrosarcomas. Herein, we tested whether the combination of this epigenetic drug to a standard anticancer therapy may enhance the response to each drug in these bone tumors. Methods: Two chondrosarcoma cell...
Main Authors: | Eva Lhuissier, Juliette Aury-Landas, Marion Lenté, Karim Boumediene, Catherine Baugé |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/18/4648 |
Similar Items
-
Epigenetic Abnormalities in Chondrosarcoma
by: Michał Bereza, et al.
Published: (2023-02-01) -
Subglottic Chondrosarcoma Presenting Only Mild Acute-Onset Dyspnea: A Case Report and Review of the Literature
by: Su-wei Tsai, et al.
Published: (2014-01-01) -
Chondrosarcoma of the larynx: a case report
by: Şenol Civelek, et al.
Published: (2006-03-01) -
Chondrosarcoma: A Clinical Review
by: Aaron Gazendam, et al.
Published: (2023-03-01) -
Huge Chondrosarcoma of Shoulder
by: Muthana Al Assal, et al.
Published: (2013-06-01)